Drug & intervention

raloxifene

RxCUI 72143

Clinical trials15
Recruiting0
Related conditions18
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Raloxifene

Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth. Common side effects include hot flashes, leg cramps, swelling, and joint pain. Severe side effects may include blood clots and stroke. Use during pregnancy may harm the baby. The medication may worsen menstrual symptoms. Raloxifene is a selective estrogen receptor modulator (SERM) and therefore a mixed agonist–antagonist of the estrogen receptor (ER). It has estrogenic effects in bone and antiestrogenic effects in the breasts and uterus. Raloxifene was approved for medical use in the United States in 1997. It is available as a generic medication. In 2020, it was the 292nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

15 shown
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum DisorderNCT03043820 · 2016-08-01
COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal WomenNCT01573637 · 2011-07-01
COMPLETED
Raloxifene in Treatment of Schizophrenia and Schizoaffective DisorderNCT01280305 · 2011-03-01
UNKNOWN
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate CancerNCT01050842 · 2010-02-01
COMPLETED
Raloxifene for Women With Alzheimer's DiseaseNCT00368459 · 2006-08-01
COMPLETED
Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal WomenNCT01041092 · 2004-06-01
COMPLETED
The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot StudyNCT00206557 · 2002-10-01
COMPLETED
Cognition in the Study of Tamoxifen and RaloxifeneNCT00687102 · 2001-10-01
COMPLETED
Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's DiseaseNCT00065767 · 2001-09-01
COMPLETED
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast CancerNCT00031811 · 2001-03-01
COMPLETED
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast CancerNCT00031850 · 2000-03-01
COMPLETED
AFTER: Altering Fat Through Estrogen and RaloxifeneNCT00149604 · 2000-03-01
COMPLETED
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenNCT00003906 · 1999-05-01
COMPLETED
Raloxifene in Preventing Breast Cancer in Premenopausal WomenNCT00019500 · 1998-12-01
COMPLETED
Raloxifene Use for The HeartNCT00190593 · 1998-06-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.